Dashboard
Manage Tickers

RVTYREVVITY, INC.

NYSE perkinelmer.com


$ 104.00 $ 1.56 (1.52 %)    

Thursday, 09-May-2024 15:34:10 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 440.76 $ 0.30 (0.07 %)
DIA $ 393.89 $ 3.78 (0.97 %)
SPY $ 519.64 $ 2.20 (0.43 %)
TLT $ 90.66 $ 0.62 (0.69 %)
GLD $ 216.32 $ 1.62 (0.75 %)
$ 102.83
$ 102.44
$ 103.15 x 100
$ 0.00 x 0
$ 102.44 - $ 104.00
$ 79.39 - $ 131.69
489,319
na
12.69B
$ 0.90
$ 84.80
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-07-2023 10-01-2023 10-Q
4 08-09-2023 07-02-2023 10-Q
5 05-12-2023 04-02-2023 10-Q
6 03-01-2023 01-01-2023 10-K
7 11-14-2022 10-02-2022 10-Q
8 08-09-2022 07-03-2022 10-Q
9 05-10-2022 04-03-2022 10-Q
10 03-03-2022 01-02-2022 10-K
11 11-09-2021 10-03-2021 10-Q
12 08-10-2021 07-04-2021 10-Q
13 05-11-2021 04-04-2021 10-Q
14 03-02-2021 01-03-2021 10-K
15 11-10-2020 10-04-2020 10-Q
16 08-11-2020 07-05-2020 10-Q
17 05-12-2020 04-05-2020 10-Q
18 02-25-2020 12-29-2019 10-K
19 11-05-2019 09-29-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-26-2019 12-30-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 07-01-2018 10-Q
25 05-08-2018 04-01-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 10-01-2017 10-Q
28 08-08-2017 07-02-2017 10-Q
29 05-09-2017 04-02-2017 10-Q
30 02-28-2017 01-01-2017 10-K
31 11-08-2016 10-02-2016 10-Q
32 08-09-2016 07-03-2016 10-Q
33 05-10-2016 04-03-2016 10-Q
34 03-01-2016 01-03-2016 10-K
35 11-10-2015 10-04-2015 10-Q
36 08-04-2015 06-28-2015 10-Q
37 05-05-2015 03-29-2015 10-Q
38 02-24-2015 12-28-2014 10-K
39 11-04-2014 09-28-2014 10-Q
40 08-05-2014 06-29-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

baird-maintains-outperform-on-revvity-raises-price-target-to-127
Baird Maintains Outperform on Revvity, Rai...
04/30/2024 16:08:17

Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $126 to $127.

4-analysts-have-this-to-say-about-revvity
4 Analysts Have This To Say About Revvity
04/30/2024 16:01:17

td-cowen-maintains-buy-on-revvity-raises-price-target-to-130
TD Cowen Maintains Buy on Revvity, Raises ...
04/30/2024 15:18:50

TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $123 to $130.

us-stocks-kick-off-the-week-in-the-green-tesla-rockets-on-chinas-fsd-approval-yen-rallies-whats-driving-markets-monday
US Stocks Kick Off The Week In The Green, ...
04/29/2024 18:14:53

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events...

revvity-reaffirms-its-2024-adjusted-eps-guidance-of-455-475-versus-consensus-of-465-and-organic-growth-guidance-of-1-3
Revvity Reaffirms Its 2024 Adjusted EPS Gu...
04/29/2024 10:06:32

revvity-revises-2024-revenue-forecast-to-276b-282b-from-prior-guidance-of-279b-285b-versus-consensus-of-281b
Revvity Revises 2024 Revenue Forecast To $...
04/29/2024 10:04:36

revvity-q1-2024-adj-eps-098-beats-093-estimate-sales-649920m-beat-646843m-estimate
Revvity Q1 2024 Adj EPS $0.98 Beats $0.93 ...
04/29/2024 10:01:29

Revvity (NYSE:RVTY) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.93 by 5.38 p...

revvity-announced-the-launch-of-the-auto-pure-2400-liquid-handler-from-allsheng-for-use-with-the-t-spottb-test
Revvity Announced The Launch Of The Auto-p...
04/24/2024 10:10:10

enphase-energy-reports-weak-results-joins-lithia-motors-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Enphase Energy Reports Weak Results, Joins...
04/24/2024 10:02:25

revvity-to-launch-signals-synergy-software-solution-designed-to-drive-greater-collaboration-project-management-and-data-exchange-between-pharmaceutical-and-biotechnology-sponsors-with-their-external-contract-partners
Revvity To Launch Signals Synergy, Softwar...
04/15/2024 10:29:37

massachusetts-superior-court-has-granted-a-preliminary-injunction-compelling-cloud-software-group-to-comply-with-its-contractual-obligations-under-its-strategic-partner-agreements-with-revvity
Massachusetts Superior Court Has Granted A...
04/02/2024 10:16:33

revvity-reaffirms-2024-full-year-guidance-of-total-revenue-of-279b-285b-est-2818b-adjusted-eps-of-455-475-est-466
Revvity Reaffirms 2024 Full Year Guidance ...
03/20/2024 21:04:51

revvity-files-complaint-against-cloud-software-group-in-massachusetts-superior-court-seeks-injunctive-relief
Revvity Files Complaint Against Cloud Soft...
03/20/2024 21:02:44

revvitys-software-and-informatics-division-revvity-signals-software-is-introducing-the-new-signals-chemdraw-offering-the-latest-advancement-in-the-revvity-signals-software-portfolio
Revvity's Software And Informatics Divisio...
03/18/2024 10:03:41

revvity-signals-software-unveils-signals-clinical-solution-to-accelerate-critical-clinical-trial-insights-and-data-driven-decisions
Revvity Signals Software Unveils Signals C...
02/12/2024 21:09:54

- Centralized data science platform streamlines clinical study data management for swift, insight-driven clinical decisions and...

stifel-maintains-hold-on-revvity-raises-price-target-to-110
Stifel Maintains Hold on Revvity, Raises P...
02/02/2024 19:45:59

Stifel analyst Daniel Arias maintains Revvity (NYSE:RVTY) with a Hold and raises the price target from $95 to $110.

keybanc-maintains-overweight-on-revvity-raises-price-target-to-126
Keybanc Maintains Overweight on Revvity, R...
02/02/2024 14:40:35

Keybanc analyst Paul Knight maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $110 to $126.

raymond-james-maintains-outperform-on-revvity-raises-price-target-to-127
Raymond James Maintains Outperform on Revv...
02/02/2024 14:01:42

Raymond James analyst Andrew Cooper maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $106 to...

revvity-forecasts-2024-revenue-of-279b-285b-and-adjusted-eps-of-455-475-versus-consensus-of-277b-and-460-respectively
Revvity Forecasts 2024 Revenue Of $2.79B-$...
02/01/2024 11:04:05

For the full year 2024, the Company forecasts total r

revvity-q4-adjusted-eps-125-beats-116-estimate-sales-69590m-beat-67794m-estimate
Revvity Q4 Adjusted EPS $1.25 Beats $1.16 ...
02/01/2024 11:01:58

Revvity (NYSE:RVTY) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.16 by 7.76 p...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION